Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

153
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
153
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

154
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
154
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

148
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
148
Neural Regulation01:37

Neural Regulation

39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

129
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic integration of Fe-MOF and biomass-derived activated carbon for enhanced ciprofloxacin adsorption: experimental insights and DFT-based mechanistic elucidation.

RSC advances·2026
Same author

<i>Tagetes patula</i> L. flower methanolic extract exhibited beneficial actions against hepatocellular carcinoma via induction of apoptosis.

Pakistan journal of pharmaceutical sciences·2026
Same author

Stunting in hospitalized children: Prevalence and modifiable nutritional risk factors at a tertiary care hospital.

Pakistan journal of medical sciences·2026
Same author

Advanced Plasma-Modified Textile Polymer Materials for Building Energy Retrofit Technologies.

Polymers·2026
Same author

Genome-wide characterization of sulphur metabolism gene families and recombination dynamics in mangrove-derived <i>Bacillus aryabhattai</i> NM1-A2 and <i>Bacillus cereus</i> NR1.

Microbial genomics·2026
Same author

Renin-angiotensin system inhibitors use and outcomes of aortic valve replacement: A systematic review and meta-analysis.

Cardiovascular revascularization medicine : including molecular interventions·2026

Related Experiment Video

Updated: Jun 13, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K

Neuroleptic malignant syndrome: A case report.

Muhammad Kashif1, Asad Tamizuddin Nizami1, Kainat Kareem Mirza1

  • 1Institute of Psychiatry, Benazir Bhutto Hospital, Rawalpindi, Pakistan.

JPMA. the Journal of the Pakistan Medical Association
|June 11, 2025
PubMed
Summary

Neuroleptic malignant syndrome (NMS) is a severe adverse drug reaction from antipsychotics. Early diagnosis and prompt management, including antipsychotic withdrawal, are crucial for patient recovery and reducing NMS risks.

Keywords:
Neuroleptic Malignant syndrome (NMS), Creatinine Phosphokinase level (CPK), 4 times a day (QID).

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.6K

Related Experiment Videos

Last Updated: Jun 13, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Psychiatry

Background:

  • Neuroleptic malignant syndrome (NMS) is a rare but life-threatening adverse drug reaction linked to antipsychotic medications.
  • It is primarily caused by dopamine D2 receptor blockade in the central nervous system.

Observation:

  • A case report of a 25-year-old male patient presenting with post-ictal behavioral disturbances is detailed.
  • The patient required rapid tranquilization and subsequently developed NMS symptoms after receiving first-generation antipsychotics.

Findings:

  • The patient exhibited markedly elevated creatinine phosphokinase (CPK) levels, reaching over 89,900 U/L.
  • Early identification of NMS and immediate intervention were critical for the patient's successful recovery.

Implications:

  • This case highlights the critical importance of prompt diagnosis and management of NMS to minimize patient morbidity and mortality.
  • Antipsychotic medication withdrawal, coupled with supportive care, forms the cornerstone of NMS treatment.